contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Analytiker

Antti Siltanen

Nexstim är verksamt inom medicinteknik. Bolaget har utvecklat en icke-invasiv teknik för hjärnstimulering som kallas SmartFocus®. Det är en navigerad magnetisk stimuleringsteknik (nTMS) med 3D-navigering som ger inriktning av TMS till det specifika området av hjärnan. Tekniken är avsedd för behandling av svår depression och kronisk neuropatisk smärta. Bolaget grundades år 2000 och har sitt huvudkontor i Helsingfors.

Medicinteknikföretaget Nexstim publicerade sin delårsrapport för januari–september där de redogjorde för investeringar i lönsam tillväxt, utvecklingen av diagnostiksystemet NBS 6 samt utökningen av sitt kliniknätverk. Enligt företaget hade 11 nya system levererats och ytterligare fyra väntade på leverans. De två nya affärer som meddelades i oktober höjde årets totala antal till 17, något högre än samma period föregående år. Efterfrågan förväntas öka mot slutet av året då sjukhusen fattar sina inköpsbeslut. Nexstim meddelade också att företaget håller på att uppdatera sin strategi, och den nya strategin kommer att publiceras senast i samband med bokslutet i början av 2025. Den kommersiella lanseringen av NBS 6-systemet är planerad till nästa år, när systemet har erhållit de nödvändiga godkännandena för diagnostiskt bruk. Dessutom går Nexstim vidare i samarbete med Sinaptica för att utveckla ett system för behandling av Alzheimers sjukdom. Nedan finns mer detaljerad information från analytikern.                    Inderes              Business news update from Nexstim - Inderes    Nexstim issued a press release on business highlights for January-September. The company said it has invested in profitable growth, development of its NBS 6 diagnostics product and expansion of its network of clinics.

Nexstim har meddelat en strategisk investering i en amerikansk organisation som erbjuder ledningstjänster för TMS-kliniker (MSO). Detta är Nexstims tredje investering i sitt kliniknätverk i rad. Minoritetsinvesteringen ger Nexstim en andel i företagets värdeskapande och tillgång till exempelvis anonymiserad behandlingsdata, vilket stöder utveckling och marknadsföring av tjänsterna. Samarbetet har ingåtts med Rapid Recovery TMS Clinic i North Carolina, och Nexstim får även återkommande intäkter samt direkt information om behandlingens effektivitet.                    Inderes              Nexstim expands its network of partner clinics - Inderes    We estimate that this investment is moderate in size and represents Nexstim's third consecutive investment in its clinic network.

Det här företaget har väckt ganska mycket diskussion bland investerare i Finland och nu finns det en färsk analys av det.                     Inderes              Seasonally calm start to the year - Inderes    Nexstim published its Q1 business update on Friday. The company reported that it delivered two NBS systems during the period.                             Nexstim published its Q1 business update on Friday. The company reported that it delivered two NBS systems during the period. Deliveries were slightly below our expectations in a seasonally slow start to the year. Based on the new data, we are modestly lowering our forecasts for the coming years. There have been no material changes in the valuation picture of the share. The stock is cheaply priced, but the risks are also elevated due to low visibility and a tight financial situation.

@antti.siltanen has done a good and high-quality analysis of this company. It’s worth reading!                    Inderes              Nexstim: The end of the year laid a firmer foundation for the future - Inderes    Revenue was slightly higher than the preliminary data suggested and the result hit our forecasts. The H2 cash flow was also at the expected zero level considering the partial transfer of cash flow to 2024 through increased trade receivables.                             The key figures were already known based on preliminary data from the beginning of the year, which were now revised. Revenue was slightly higher than the preliminary data suggested and the result hit our forecasts. The H2 cash flow was also at the expected zero level considering the partial transfer of cash flow to 2024 through increased trade receivables. The report did not contain any surprises, so forecast changes were small. Nexstim expects increasing revenue and earnings, which disperses concerns related to cash flow adequacy. We expect the company to continue on the path of profitable growth, although the cashflow is likely to remain negative this year.

Ägarna till Nexstim har en spännande dag på tisdag.                    Inderes              Nexstim H2 on Tuesday: A record-breaking end to the year - Inderes    The company issued a profit warning early in the year, saying that full-year EBITDA would be negative (guidance: Positive EBITDA). H2 revenue level of 4.5 MEUR (H2’22: 2.7 MEUR) is already known thanks to the profit warning. Revenue is the best in...

Inderes              Nexstim’s system sales progressed well in H2 - Inderes    Nexstim’s H2 was positive in terms of announced system sales. During the reporting period, the company announced 16 system sales of which 11 occurred in Q4. The total number of deals will only be revealed in the H2 report as not all deals are...                             Nexstim’s H2 was positive in terms of announced system sales. During the reporting period, the company announced 16 system sales of which 11 occurred in Q4. The total number of deals will only be revealed in the H2 report as not all deals are announced with a press release. Depending on the final number, the period may be the best in the company’s history. This provides a positive base for this year, when we expect licensing revenue to start with Magnus Medical commercializing the system. Sales also needs to be on an upward trend to achieve more permanent profitability.

Nu analys på Nexstim utgavs i dag Nexstim: New year starts in a mixed atmosphere - Inderes

Nexstim

Nexstim’s 2023 revenue grew to some 7 MEUR, but EBITDA was below the guidance. Thanks to good sales in late 2023, we raise our forecasts slightly. The valuation picture is moderate, but the company’s situation is also twofold.

<p>Nexstim’s 2023 revenue grew to some 7 MEUR, but EBITDA was below the guidance. Thanks to good sales in late 2023, we raise our forecasts slightly. The valuation picture is moderate, but the company’s situation is also twofold. Continued good development and license income that will start later can turn cash flow around and enable future growth investments. On the other hand, a seasonally quieter H1 can freeze moneyflows and increase the likelihood of a financing round , putting pressure on the stock.</p> <p> </p> 

	2022	23e	24e
Omsättning	9,5	7,0	8,8
tillväxt-%	48,91 %	−26,56 %	25,72 %
EBIT (adj.)	0,8	−1,1	−0,4
EBIT-%	8,79 %	−15,65 %	−4,79 %
EPS (adj.)	0,18	−0,17	−0,07
Utdelning	0,00	0,00	0,00
Direktavkastning
P/E (just.)	22,85	-	-
EV/EBITDA	22,00	-	193,04

Nexstim

Key Estimate Figures03/01

Beställ vårt nyhetsbrev — inget användarkonto krävs!